Table 7

Tailoring direct oral anticoagulant (DOAC) choice to individual patient profiles

Patient characteristics	Choice of DOAC
High risk for gastrointestinal bleeding	apixaban 5 mg BD dabigatran 110 mg BD
HAS-BLED ≥ 3	dabigatran 110 mg BD apixaban 5 mg BD edoxaban 60 mg OD
Dyspepsia/gastric symptoms	apixaban 5 mg BD rivaroxiban 20 mg OD
Once daily dosing	rivaroxiban 20 mg OD edoxaban 60 mg OD
Recurrent stroke/TIA	dabigatran 150 mg BD
Moderate renal impairment (CrCl 30-49 ml/min)	apixaban 5 mg BD rivaroxiban 15 mg OD dabigatran 110 mg BD edoxaban 30 mg OD
Severe renal impairment (CrCl 15-29 ml/min)	edoxaban 30 mg OD apixaban 2.5 mg OD

TIA = transient ischaemic attack; CrCl = creatinine clearance